In collaboration with Stanford University, IBT is developing monoclonal antibody (mAb) therapeutics for hepatitis C (HCV). IBT and its collaborators have identified a novel series of neutralizing antibodies against this chronic disease. A unique feature of these antibodies is the ability to prevent the virus from developing resistance. We are currently conducting preclinical studies to characterize and evaluate the candidates.